We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

373 hedge funds and large institutions have $9.87B invested in Jazz Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 121 increasing their positions, 146 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 30

9% more capital invested

Capital invested by funds: $9.08B → $9.87B (+$788M)

5% more funds holding

Funds holding: 354 → 373 (+19)

17% less repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 146

28% less funds holding in top 10

Funds holding in top 10: 18 → 13 (-5)

52% less call options, than puts

Call options by funds: $54M | Put options by funds: $113M

Holders
373
Holders Change
+19
Holders Change %
+5.37%
% of All Funds
10.05%
Holding in Top 10
13
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-27.78%
% of All Funds
0.35%
New
51
Increased
121
Reduced
146
Closed
30
Calls
$54M
Puts
$113M
Net Calls
-$59.1M
Net Calls Change
-$28.4M

Top Buyers

1
BFA
BlackRock Fund Advisors
California
+$272M
2
BIT
BlackRock Institutional Trust
California
+$261M
3
PC
PointState Capital
New York
+$76.6M
4
BG
BlackRock Group
United Kingdom
+$71.1M
5
NC
Nicholas Company
Wisconsin
+$60.4M

Top Sellers

1
Wells Fargo
Wells Fargo
California
-$68.1M
2
JHIU
Janus Henderson Investors US
Colorado
-$65.5M
3
HM
HealthCor Management
New York
-$56.2M
4
LPC
Lone Pine Capital
Connecticut
-$45.1M
5
Franklin Resources
Franklin Resources
California
-$27.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
VCAM
151
Valentine Capital Asset Management
California
$3.92M -$3.48M -19,386 -47%
M&T Bank
152
M&T Bank
New York
$3.8M -$212K -1,181 -5%
OAM
153
Oxford Asset Management
United Kingdom
$3.71M -$5.49M -30,595 -59%
HHC
154
Hutchin Hill Capital
New York
$3.66M +$3.74M +20,800 New
PVI
155
Pura Vida Investments
New York
$3.46M -$2.6M -14,500 -45%
TAM
156
Tealwood Asset Management
Minnesota
$3.36M +$155K +864 +5%
LPL Financial
157
LPL Financial
California
$3.27M +$575K +3,203 +21%
Renaissance Technologies
158
Renaissance Technologies
New York
$3.22M +$3.29M +18,300 New
Barclays
159
Barclays
United Kingdom
$3.13M +$1.32M +7,333 +70%
SGH
160
Sivik Global Healthcare
Connecticut
$3.05M -$934K -5,200 -23%
ACM
161
Atika Capital Management
New York
$2.99M +$611K +3,400 +25%
FAF
162
Fjarde Ap-fonden
Sweden
$2.94M -$162K -901 -5%
Baird Financial Group
163
Baird Financial Group
Wisconsin
$2.92M +$2.98M +16,567 New
VanEck Associates
164
VanEck Associates
New York
$2.85M +$2.9M +16,173 New
Capital Fund Management (CFM)
165
Capital Fund Management (CFM)
France
$2.82M +$2.59M +14,417 +892%
EVM
166
Eaton Vance Management
Massachusetts
$2.79M -$466K -2,596 -14%
Royal Bank of Canada
167
Royal Bank of Canada
Ontario, Canada
$2.74M +$336K +1,872 +14%
WCBA
168
Weaver C. Barksdale & Associates
Tennessee
$2.73M – – –
Public Employees Retirement Association of Colorado
169
Public Employees Retirement Association of Colorado
Colorado
$2.72M +$3.59K +20 +0.1%
BOS
170
Bingham Osborn & Scarborough
California
$2.71M -$264K -1,471 -9%
DCMM
171
DG Capital Management (Massachusetts)
Massachusetts
$2.66M +$294K +1,635 +12%
IRF
172
IBM Retirement Fund
New York
$2.63M +$122K +677 +5%
TD Asset Management
173
TD Asset Management
Ontario, Canada
$2.62M -$53.9K -300 -2%
Marshall Wace
174
Marshall Wace
United Kingdom
$2.6M +$2.65M +14,757 New
FCI
175
Financial Counselors Inc
Kansas
$2.58M +$302K +1,683 +13%
5 6
7
8 9

JAZZ Hedge Fund Activity: Q2 2015 in Review

373 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2015, worth a combined $9.87B — up 8.7% from $9.08B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new JAZZ positions and 30 closed out — a net gain of 21 holders — while 121 added to existing stakes and 146 trimmed.

The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $272M. The largest seller was Wells Fargo, cutting an estimated $68.1M.

  • 373 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2015, up from 354 in Q1 2015.
  • Funds reported $9.87B of Jazz Pharmaceuticals stock for Q2 2015, up 8.7% quarter-over-quarter.
  • 51 funds opened new Jazz Pharmaceuticals positions in Q2 2015 and 30 closed out, a net change of +21 holders.
  • The largest Jazz Pharmaceuticals buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $272M added.
  • The largest Jazz Pharmaceuticals seller in Q2 2015 was Wells Fargo, an estimated $68.1M sold.

Based on aggregated 13F filings for Q2 2015.